Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bupropion hydrochloride sustained-release capsules and preparation method thereof

A technology of bupropion hydrochloride and sustained-release capsules, which is applied in the fields of pharmaceutical formulations, medical preparations containing active ingredients, nervous system diseases, etc., and can solve the problems of gastrointestinal motility rate, obvious individual differences, and epilepsy. To achieve the effects of reducing the incidence of adverse reactions, stabilizing changes in blood drug concentration, and improving compliance

Active Publication Date: 2018-11-27
上海爱的发制药有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, excessive application of ordinary tablets may cause epilepsy (incidence rate is about 0.4%)
However, the existing sustained-release tablets are skeleton sustained-release tablets made of high viscosity or water-insoluble materials, which are easily disturbed by various factors in the body, especially affected by the peristaltic rate of the gastrointestinal tract, and individual differences are obvious, resulting in curative effect. bad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] The preferred embodiments of the present invention are given below to describe the technical solution of the present invention in detail.

[0014] The bupropion hydrochloride sustained-release capsule of the present invention is made up of the following components, calculated by weight percentage, 62.50% bupropion hydrochloride, 6.25% tartaric acid, 9.26% sugar pills, 4.17% povidone K30 (referred to as PVPK30), 6.94% palmitic acid stearate, 0.46% acrylic resin RS100, 9.26% acrylic resin NE30D, 0.93% talc, 0.23% yellow iron oxide. Tartaric acid is a stabilizing agent to keep the stability of bupropion hydrochloride in the preparation. Povidone K30 and acrylic resin RS100 are used as adhesives. Glyceryl Palmitate Stearate is used in the barrier coating. Acrylic resin NE30D is used for sustained release coating. Talc is a lubricant. Yellow iron oxide is a coloring agent.

[0015] The preparation method of the bupropion hydrochloride sustained-release capsules of the p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a bupropion hydrochloride sustained-release capsule and a preparation method thereof. The bupropion hydrochloride sustained-release capsule consists of the following components in percentage by weight: 62.50% of bupropion hydrochloride, 6.25% of tartaric acid, 9.26% of rotula, 4.17% of povidone K30, 6.94% of glyceryl palmitostearate, 0.46% of acrylic resin RS100, 9.26% of acrylic resin NE30D, 0.93% of talcum powder and 0.23% of yellow ferric oxide. The bupropion hydrochloride sustained-release capsule is uniform and stable in releasing, after a patient orally takes the bupropion hydrochloride sustained-release capsule, blood concentration is changed stably, after everyday medicine taking frequency is reduced, occurrence rate of adverse reaction is reduced obviously, and compliance of a patient is improved.

Description

technical field [0001] The invention relates to a capsule and a preparation method thereof, in particular to a bupropion hydrochloride sustained-release capsule and a preparation method thereof Background technique [0002] Bupropion hydrochloride is an aminoketone drug that has a weak inhibitory effect on the uptake of norepinephrine, 5-hydroxytryptamine (5-HT) and dopamine. g of bupropion hydrochloride sustained-release tablets can also be used as a smoking cessation preparation. However, excessive application of ordinary tablets may lead to epilepsy (the incidence rate is about 0.4%). However, the existing sustained-release tablets are skeleton sustained-release tablets made of high viscosity or water-insoluble materials, which are easily disturbed by various factors in the body, especially affected by the peristaltic rate of the gastrointestinal tract, and individual differences are obvious, resulting in curative effect. bad. Contents of the invention [0003] The t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/60A61K31/137A61P25/24A61P25/34
Inventor 雷迪克
Owner 上海爱的发制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com